Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis
- PMID: 31536748
- DOI: 10.1016/j.jhep.2019.09.007
Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis
Abstract
Background & aims: Cholangiocarcinoma (CCA) carries a poor prognosis, is increasing in incidence and its causes are poorly understood. Although some risk factors are known, they vary globally and collectively account for a minority of cases. The aim of this study was to perform a comprehensive meta-analysis of risk factors for intrahepatic (iCCA) and extrahepatic cholangiocarcinoma (eCCA), from Eastern and Western world studies.
Methods: A literature search of case-control studies was performed to identify potential risk factors for iCCA and eCCA. Pooled odds ratios (ORs) with 95% CIs and heterogeneity were calculated. Funnel plots were used to assess publication bias, and meta-regression was used to select risk factors for comparison between Eastern and Western studies.
Results: A total of 13 risk factors were selected from 25 case-control studies in 7 geographically diverse countries. The strongest risk factors for both iCCA and eCCA were biliary cysts and stones, cirrhosis, hepatitis B and hepatitis C. Choledochal cysts conferred the greatest risk of both iCCA and eCCA with pooled ORs of 26.71 (95% CI 15.80-45.16) and 34.94 (24.36-50.12), respectively. No significant associations were found between hypertension and obesity for either iCCA or eCCA. Comparing Eastern and Western populations, there was a difference for the association of hepatitis B with iCCA (coefficient = -0.15195; 95% CI -0.278 to -0.025; p = 0.022).
Conclusion: This is the most comprehensive meta-analysis of CCA risk factors to date. Some risk factors, such as diabetes, although less strong, are increasing globally and may be contributing to rising rates of this cancer.
Lay summary: Cholangiocarcinoma (CCA) is a cancer arising in the bile ducts inside (intrahepatic CCA) and connected to the liver (extrahepatic CCA). It is a very aggressive cancer: 95% of patients die within 5 years. CCA rates are increasing globally, but the causes of CCA are poorly understood. The few risk factors that are known account for only a minority of cases. In this study, we found that the strongest risk factors for both intrahepatic and extrahepatic CCA are cysts and stones in the bile ducts, cirrhosis, and hepatitis B and C viruses. Some risk factors for CCA, such as diabetes, although less strong, are increasing globally and may be contributing to rising rates of CCA.
Keywords: Cholangiocarcinoma; Meta-analysis; Risk factors.
Copyright © 2019 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Comment in
-
Letter regarding [Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis].J Hepatol. 2020 Jun;72(6):1216. doi: 10.1016/j.jhep.2020.01.022. Epub 2020 Mar 17. J Hepatol. 2020. PMID: 32197800 No abstract available.
-
Reply to: 'Letter regarding [Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis]'.J Hepatol. 2020 Jun;72(6):1217. doi: 10.1016/j.jhep.2020.02.029. Epub 2020 Mar 24. J Hepatol. 2020. PMID: 32216990 No abstract available.
-
Challenges in elucidating cholangiocarcinoma etiology.Hepatobiliary Surg Nutr. 2020 Aug;9(4):537-539. doi: 10.21037/hbsn.2020.02.03. Hepatobiliary Surg Nutr. 2020. PMID: 32832513 Free PMC article. No abstract available.
Similar articles
-
Viral hepatitis B and C infections increase the risks of intrahepatic and extrahepatic cholangiocarcinoma: Evidence from a systematic review and meta-analysis.Turk J Gastroenterol. 2020 Mar;31(3):246-256. doi: 10.5152/tjg.2020.19056. Turk J Gastroenterol. 2020. PMID: 32343237 Free PMC article.
-
Hepatitis C virus infection and the risk of intrahepatic cholangiocarcinoma and extrahepatic cholangiocarcinoma: evidence from a systematic review and meta-analysis of 16 case-control studies.World J Surg Oncol. 2015 Apr 23;13:161. doi: 10.1186/s12957-015-0583-9. World J Surg Oncol. 2015. PMID: 25903488 Free PMC article.
-
New epidemiologic trends in cholangiocarcinoma.Clin Res Hepatol Gastroenterol. 2023 Nov;47(9):102223. doi: 10.1016/j.clinre.2023.102223. Epub 2023 Oct 4. Clin Res Hepatol Gastroenterol. 2023. PMID: 37797807 Review.
-
Cholangiocarcinoma miscoding in hepatobiliary centres.Eur J Surg Oncol. 2021 Mar;47(3 Pt B):635-639. doi: 10.1016/j.ejso.2020.09.039. Epub 2020 Oct 1. Eur J Surg Oncol. 2021. PMID: 33032867
-
Temporal Changes in Cholangiocarcinoma Incidence and Mortality in the United States from 2001 to 2017.Oncologist. 2022 Oct 1;27(10):874-883. doi: 10.1093/oncolo/oyac150. Oncologist. 2022. PMID: 35972334 Free PMC article.
Cited by
-
Research progress and prospect of postoperative adjuvant therapy for resectable intrahepatic cholangiocarcinoma.Front Pharmacol. 2024 Aug 7;15:1432603. doi: 10.3389/fphar.2024.1432603. eCollection 2024. Front Pharmacol. 2024. PMID: 39170710 Free PMC article. Review.
-
Postpartum related intrahepatic cholangiocarcinoma with FGFR2 fusion and severe hyperbilirubinemia with response to FGFR inhibitor pemigatinib: case report and review.J Gastrointest Oncol. 2023 Dec 31;14(6):2627-2636. doi: 10.21037/jgo-23-693. Epub 2023 Dec 12. J Gastrointest Oncol. 2023. PMID: 38196530 Free PMC article.
-
Incidence and Long-Term Outcomes of Biliary Tract Cancers in Olmsted County, Minnesota from 1976 to 2018.Cancers (Basel). 2024 Jul 31;16(15):2720. doi: 10.3390/cancers16152720. Cancers (Basel). 2024. PMID: 39123448 Free PMC article.
-
Cost-effectiveness of pembrolizumab plus chemotherapy vs. chemotherapy as first-line treatment for advanced biliary tract cancer in China and the US.Front Pharmacol. 2024 Aug 14;15:1393559. doi: 10.3389/fphar.2024.1393559. eCollection 2024. Front Pharmacol. 2024. PMID: 39206260 Free PMC article.
-
Proteomic and single-cell landscape reveals novel pathogenic mechanisms of HBV-infected intrahepatic cholangiocarcinoma.iScience. 2023 Jan 18;26(2):106003. doi: 10.1016/j.isci.2023.106003. eCollection 2023 Feb 17. iScience. 2023. PMID: 36852159 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical